Hologic delivered a robust performance in the fourth quarter of fiscal 2025, with total revenue reaching $1,049.5 million, marking a 6.2% increase year-over-year. Both GAAP and non-GAAP diluted EPS saw significant growth, rising by 9.2% and 11.9% respectively. The company also generated strong cash flow from operations and maintained a healthy financial position.
Revenue for Q4 2025 increased by 6.2% to $1,049.5 million, demonstrating solid top-line growth.
GAAP diluted EPS grew by 9.2% to $0.83, and non-GAAP diluted EPS increased by 11.9% to $1.13, reflecting improved profitability.
Diagnostics revenue grew by 2.4% to $454.1 million, driven by core U.S. molecular diagnostics sales despite lower COVID-19 assay sales.
Breast Health revenue increased by 4.8% to $393.7 million, primarily due to strong interventional product sales and improved U.S. sales execution.
Hologic is not providing annual or quarterly financial guidance for fiscal year 2026 due to the pending acquisition by Blackstone and TPG.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance